Uncategorized
GEFAL results support CATT, IVAN findings
SEATTLE — Like the CATT and IVAN trials, the French Evaluation Group Avastin Versus Lucentis found also that bevacizumab is non-inferior to ranibizumab, the GEFAL investigators reported here.“We found that, for our primary outcome, which is visual acuity, bevacizumab is non-inferior to ranibizumab,” study author Laurent Kodjikian, MD, PhD, said in a press briefing at the Association for Research in Vision and Ophthalmology meeting. The mean visual acuity difference between the two drugs was 1.89 letters, which is clinically meaningless, Kodjikian said.